IP
JAZZ icon

Intellectus Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Intellectus Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-16
Closed -$3K – 405
2018
Q3 		$3K Hold
16
– – ﹤0.01% 547
2018
Q2 		$3K Hold
16
– – ﹤0.01% 555
2018
Q1 		$2K Hold
16
– – ﹤0.01% 567
2017
Q4 		$2K Buy
+16
New +$2.22K ﹤0.01% 580

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Intellectus Partners's JAZZ Position: Q4 2018 in Review

Intellectus Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 16 shares — an estimated $3K sold.

Intellectus Partners first reported a position in JAZZ in Q4 2017 and held it in 4 quarters. The position peaked at $3K in Q3 2018. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

  • Intellectus Partners reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Intellectus Partners sold 16 Jazz Pharmaceuticals shares in Q4 2018, an estimated $3K.
  • Intellectus Partners first reported a position in Jazz Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • Intellectus Partners's Jazz Pharmaceuticals position peaked at $3K in Q3 2018.
  • 417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.